These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1555988)

  • 1. Comparative effects of hydralazine on perfusion of KHT tumor, kidney and liver and on renal function in mice.
    Honess DJ; Bleehen NM
    Int J Radiat Oncol Biol Phys; 1992; 22(5):953-61. PubMed ID: 1555988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the radiosensitising agent nicotinamide on relative tissue perfusion and kidney function in C3H mice.
    Honess DJ; Bleehen NM
    Radiother Oncol; 1993 May; 27(2):140-8. PubMed ID: 8356224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of two tumor blood flow modifiers, hydralazine and flavone acetic acid, on KHT tumours and normal tissues in mice.
    Honess DJ; Bleehen NM
    Int J Radiat Biol; 1991; 60(1-2):249-53. PubMed ID: 1677979
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of hydralazine on the blood flow in RIF-1 tumors and normal tissues of mice.
    Lin JC; Song CW
    Radiat Res; 1990 Nov; 124(2):171-7. PubMed ID: 2247597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentoxifylline: its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice.
    Honess DJ; Dennis IF; Bleehen NM
    Radiother Oncol; 1993 Sep; 28(3):208-18. PubMed ID: 8255998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood flow modification in the SCCVII tumor: effects of 5-hydroxytryptamine, hydralazine, and propranolol.
    Peters CE; Chaplin DJ
    Int J Radiat Oncol Biol Phys; 1992; 22(3):463-5. PubMed ID: 1735679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice.
    Bibby MC; Loadman PM; al-Ghabban AF; Double JA
    Br J Cancer; 1992 Mar; 65(3):347-50. PubMed ID: 1558786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of calcium channel blockers on renal function in mice.
    Honess DJ; Bleehen NM
    Int J Radiat Oncol Biol Phys; 1992; 22(3):443-6. PubMed ID: 1735675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BW12C: effects on tumour hypoxia, tumour thermosensitivity and relative tumour and normal tissue perfusion in C3H mice.
    Honess DJ; Hu DE; Bleehen NM
    Br J Cancer; 1991 Oct; 64(4):715-22. PubMed ID: 1911220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of fluorine-19 nuclear magnetic resonance spectroscopy and hydralazine for measuring dynamic changes in blood perfusion volume in tumors in mice.
    Thomas C; Counsell C; Wood P; Adams GE
    J Natl Cancer Inst; 1992 Feb; 84(3):174-80. PubMed ID: 1542128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological evidence for nonperfused vasculature in a murine tumor following hydralazine administration.
    Trotter MJ; Acker BD; Chaplin DJ
    Int J Radiat Oncol Biol Phys; 1989 Oct; 17(4):785-9. PubMed ID: 2777668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of hydralazine on tumor and normal tissue blood perfusion by MRI.
    Belfi CA; Paul CR; Shan S; Ngo FQ
    Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):473-9. PubMed ID: 8005802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hydralazine on the blood flow in tumors and normal tissues in rats.
    Hasegawa T; Song CW
    Int J Radiat Oncol Biol Phys; 1991 May; 20(5):1001-7. PubMed ID: 2022499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the renal vasodilator prodrug CGP 22 979A and its parent compound CGP 18 137A on renal and central hemodynamics in conscious spontaneously hypertensive rats.
    Nievelstein HM; van Essen H; Hornsveld R; Struyker-Boudier HA; Smits JF
    J Pharmacol Exp Ther; 1985 Dec; 235(3):778-82. PubMed ID: 4078731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of changes in tumor blood perfusion after hydralazine treatment by dynamic paramagnetic-enhanced magnetic resonance imaging.
    Belfi CA; Ting LL; Hassenbusch SJ; Tefft M; Ngo FQ
    Int J Radiat Oncol Biol Phys; 1992; 22(3):477-82. PubMed ID: 1735682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal response of tumor vasculature to vasoactive drugs.
    Chan RC; Babbs CF; Vetter RJ; Lamar CH
    J Natl Cancer Inst; 1984 Jan; 72(1):145-50. PubMed ID: 6582294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological modification of tumor blood flow: lack of correlation between alteration of mean arterial blood pressure and changes in tumor perfusion.
    Stone HB; Minchinton AI; Lemmon M; Menke D; Brown JM
    Int J Radiat Oncol Biol Phys; 1992; 22(1):79-86. PubMed ID: 1530755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of hydralazine administration on oxygenation in spontaneous and transplanted tumor models.
    Fenton BM
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):799-808. PubMed ID: 11172963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy with ACE inhibitors in chronic heart failure and limited kidney function].
    Osterziel KJ; Nagel F; Dietz R
    Z Kardiol; 1994; 83 Suppl 4():81-7. PubMed ID: 7856286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of pH of normal and malignant mouse tissue by hydralazine and glucose, with and without breathing of 5% CO2 and 95% air.
    Tobari C; Van Kersen I; Hahn GM
    Cancer Res; 1988 Mar; 48(6):1543-7. PubMed ID: 3125964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.